- Home
- / Evaxion Biotech
Evaxion Biotech
Stock Price
$2.9
2024-10-29
Market Capitalization
$16.2 M
2024-10-29
Revenue
$7.5 M
FY, 2025
Evaxion Biotech Summary
Company Summary
- Overview
- Evaxion Biotech A/S is a company focused on the development of vaccines against cancer and infectious diseases. It discovers antigens and neo-epitopes for vaccines and antibodies using artificial intelligence. The company provides PIONEER and EDEN platforms that predict, rank, and optimize epitopes and antigens that elicit an immune response against cancers and infectious diseases.
- Type
- Public
- Status
- Active
- Founded
- 2008
- HQ
- København, DK | view all locations
- Website
- http://evaxion-biotech.com/
- Cybersecurity rating
Table of Contents
Key People
Marianne Sogaard, Chairman of the Board
Andreas Holm Mattsson, Co-Founder and Chief Innovation & Culture Officer
Lars Holtug, Director
Operating MetricsView all
Patents (UK)
2
FY, 2020
Patent Families
20
FY, 2020
Patents (US)
6
FY, 2020
LocationsView all
1 location detected
København HQ
Denmark
Bredgade 34e, 4. sal
Evaxion Biotech Financials
Summary Financials
- Revenue (FY, 2025)
- $7.5M
- Gross profit (FY, 2025)
- $7.5M
- Net income (FY, 2025)
- ($7.7M)
- Cash (FY, 2025)
- $23.2M
- EBIT (FY, 2025)
- ($9.2M)
- Enterprise value
- $502.2K